CompletedPhase 2NCT00099489
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biogen
- Principal Investigator
- Allan Ropper, MDTufts University School of Medicine, St. Elizabeth's Medical Center
- Intervention
- Interferon Beta-1a(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2004 – 2006
Study locations (20)
- Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
- Neuromuscular Research Center, Scottsdale, Arizona, United States
- University of Florida, Jacksonville, Jacksonville, Florida, United States
- University of Miami, Miami, Florida, United States
- University of Kansas, Kansas City, Kansas, United States
- Louisiana State University, New Orleans, Louisiana, United States
- Harvard University/MGH, Boston, Massachusetts, United States
- Tufts University/ St. Elizabeths, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Weill Medical College of Cornell University, New York, New York, United States
- Raleigh Neurology Associates, Raleigh, North Carolina, United States
- University of Texas Southwestern, Dallas, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- Liverpool Hospital, Liverpool, New South Wales, Australia
- Institute of Clinical Neurosciences, Sydney, New South Wales, Australia
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00099489 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →